An acoustic coupling fluid improves intraoperative ultrasound image quality during glioma surgery: Results of a Pivotal Multicenter Study (NCT04734444)

In the operating room, removing a brain tumor is a high-stakes exercise in precision. Surgeons rely on real-time imaging to see exactly where the tumor ends and healthy brain begins, a distinction that is often invisible to the naked eye. Among the tools available, ultrasound is a workhorse because it can be used repeatedly throughout the operation without stopping the surgery. However, as the surgeon carves out the tumor, a physical problem arises that clouds the view. Once the mass is gone, the empty space is filled with a liquid used to wash away blood and debris. This liquid, usually a simple saltwater solution, behaves differently than the brain tissue surrounding it. When sound waves from the ultrasound probe hit the boundary between the liquid and the brain, they bounce back in a confusing way, creating a bright, noisy glare deep inside the image. This glare can hide small bits of remaining tumor or make healthy tissue look like it is still diseased, leaving the surgeon unsure whether to stop or keep cutting.

To solve this specific problem, a team of neurosurgeons across five hospitals in Europe tested a new liquid designed to mimic the brain itself. In a major study involving dozens of patients, they compared the standard saltwater wash against this new fluid, called SonoClear. The results showed that when the new fluid was used, the confusing glare disappeared. The images became clearer, allowing surgeons to see the edges of the tumor and the deep recesses of the surgical cavity with much greater confidence. The study confirmed that this fluid is safe to use and does not cause harm, offering a straightforward way to improve the clarity of the most critical moments in brain tumor surgery.

The challenge of seeing clearly inside the brain during surgery is not new, but the physics behind the visual distortion is specific. As a surgeon removes a glioma, a type of tumor that grows within the brain tissue, they must constantly check their progress using an ultrasound probe. This device sends sound waves into the brain and listens for the echoes to build a picture. Early in the operation, the probe sits against the brain, and the picture is clear. But as the tumor is scooped out, the cavity fills with irrigation fluid to keep the area clean. Standard medical fluids, like saline, are much thinner than brain tissue. When the ultrasound waves pass from the fluid into the brain, the sudden change in density causes the waves to scatter and create a bright, artificial signal beneath the cavity. This signal looks like a cloud of static that can either mask a tiny piece of leftover tumor or create a false alarm that looks like a tumor where there is none. Surgeons have tried to work around this by changing the angle of the probe or using different scanning techniques, but these methods depend heavily on the skill of the individual operator and do not fix the underlying mismatch between the fluid and the brain.

To address this, researchers developed a fluid that matches the acoustic properties of brain tissue. This new liquid, SonoClear, is designed to behave exactly like the brain when sound waves hit it, preventing the bright glare from forming. The study, conducted at five medical centers in Italy, Germany, and Slovakia, put this fluid to the test in a real-world surgical setting. Forty-four patients with suspected gliomas were enrolled. During the surgery, the team performed a specific sequence of events. First, they filled the surgical cavity with the standard saltwater solution and took ultrasound pictures at two critical moments: when the tumor was about eighty percent removed and when the surgeon declared the operation finished. Then, they swapped the saltwater for the new SonoClear fluid and took another set of pictures from the exact same spot, just minutes later. This "paired" approach allowed for a direct, side-by-side comparison within the same patient, ensuring that any differences in the images were due to the fluid and not the patient's unique anatomy.

The results of this comparison were striking. When the images were analyzed by an independent laboratory, the new fluid significantly reduced the noisy, bright signal that usually obscures the view. The researchers measured this by comparing the clarity of the image against the background noise, finding that the standard fluid produced nearly twice as much confusing signal as the new fluid. This reduction in noise meant that the deep parts of the surgical cavity, which are usually the hardest to see, became much more visible. The improvement was not just a number on a chart; it was a tangible difference in what the surgeons could see. Five experienced neurosurgeons, who did not know which fluid was used in which image, reviewed the pictures and rated the quality. They consistently gave higher scores to the images taken with the new fluid, noting that it was easier to tell the difference between healthy brain and remaining tumor. The average improvement in their ratings was substantial, indicating a clear shift in confidence and interpretability.

Safety was a primary concern, as introducing any new substance into the brain requires extreme caution. The study tracked every patient for thirty days after surgery and followed up with a call six months later. The researchers looked for any signs that the fluid caused complications, such as infections, seizures, or unexpected changes on post-operative MRI scans. The findings were reassuring: no serious adverse events were linked to the fluid. The few complications that did occur, such as seizures or infections, were typical risks of brain surgery itself and were not caused by the new liquid. In the patients who had follow-up MRI scans, the images showed only the expected changes from the surgery, with no evidence that the fluid remained in the brain or caused damage. This confirmed that the fluid could be used safely and removed effectively before the surgery ended.

The study concludes that this new fluid offers a significant advantage over the standard saltwater wash used in neurosurgery today. By matching the brain's natural properties, it eliminates the visual distortion that has long plagued surgeons trying to see the deepest parts of a tumor cavity. While the study focused on the quality of the images and the safety of the fluid, it did not measure whether these clearer pictures led to more tumor being removed or better long-term survival for patients. Those questions remain for future research. However, the evidence is clear that for the surgeon standing at the operating table, the new fluid provides a sharper, more reliable view at the moment when that view matters most. It turns a cloudy, ambiguous picture into a clear one, giving the medical team a better chance to distinguish between what needs to be removed and what must be left behind.